Everything below concerns Fifteen residues. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | About 1419.5 Da | Calculated from the fifteen-residue sequence |
| Residue count | 15 amino acids | Single-letter sequence GEPPPGKPADDAGLV |
| Compound class | Synthetic peptide | Produced by solid-phase synthesis |
| Synonyms | BPC 157; pentadecapeptide BPC 157 | Naming varies across suppliers and papers |
| Appearance | White to off-white powder | Typical form of the lyophilized material |
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Necrophages can be classified according to their nutritional reliance on carrion and also their level of adaptation to carrion feeding. Animals are described as 'obligate necrophages' if they use carrion as their sole or main food source and depend on carrion for survival or reproduction. The term 'specialists' is also sometimes used in recognition that these animals have traits favoring necrophagy and making other feeding behaviors difficult. For example, large wingspans facilitate the energy-efficient gliding vultures need to cover long distances in search of carrion, but reduce the agility needed to kill prey. Animals that eat carrion opportunistically and retain the traits needed to find and consume other food sources are described as 'facultative necrophages' and 'generalists'. Both obligate and facultative necrophages are sometimes sub-classified as 'wet' and 'dry' feeders. These terms differentiate animals feeding on moist, putrefying tissue from animals feeding on desiccated and keratinized tissues.
== History == In the mid-twentieth century, mumps infections among children were not viewed as a serious public health issue, but adult men may develop debilitating testicular inflammation, which posed particular difficulty among close-quartered soldiers during wartime. As a result, during World War II (1939–1945), the United States government targeted mumps for scientific research. The first experimental mumps vaccine was licensed in 1948; developed from inactivated virus, it only had short-term effectiveness. Improved vaccines became commercially available in the 1960s. In 1963, Maurice Hilleman of Merck & Co. took samples of the mumps virus from his daughter, who had contracted the disease; she became the namesake for the resulting Jeryl Lynn strain. Building on then-recent advances that had led to vaccines for polio and measles, the mumps virus strains were developed in embryonic hens' eggs and chick embryo cell cultures. The resulting strains of virus were less well-suited for human cells, and are thus said to be attenuated. They are sometimes referred to as neuroattenuated in the sense that these strains are less virulent to human neurons than the wild strains. Hilleman's work led to the first effective mumps vaccine, called Mumpsvax. Licensed in 1967, its four-year development set a record for fastest development of a new vaccine, a record later surpassed by the COVID-19 vaccine, which was developed in less than a year.
=== Oxidant === In organic synthesis, DMSO is used as a mild oxidant. It forms the basis of several selective sulfonium-based oxidation reactions including the Pfitzner–Moffatt oxidation, Corey–Kim oxidation and the Swern oxidation. The Kornblum oxidation is conceptually similar. These methods all involve formation of an intermediate sulfonium species (R2S+OX) where X is a heteroatom attached to oxygen).
glutamate (reduced nicotinamide adenine dinucleotide) synthase, glutamate synthase (NADH), L-glutamate synthetase(NADH), NADH-dependent glutamate synthase, NADH-glutamate synthase, and NADH-Glutamine oxoglutarate aminotransferase (NADH-GOGAT).
Sources: en.wikipedia.org
He then participated in the mixed doubles match with Siegemund, against Australia's Storm Hunter and Matthew Ebden. Saving two match points, Zverev and Siegemund won their match in a match tiebreak score of 15–13, and with Kerber's earlier narrow win against Alja Tomljanovic, Team Germany qualified for the final against Team Poland. After Kerber was unsuccessful against the Polish world No. 1, Iga Swiatek, Zverev made a critical comeback win against Poland's Hubert Hurkacz, saving two championship points in the process and levelled the tie 1–1. Partnering once more with Siegemund, Zverev played the mixed doubles match and successfully defeated the Polish pair of Hurkacz and Swiatek in a decisive match tiebreak and won the United Cup for Team Germany. In the process, he won his first team event since the Laver Cup in 2021. In 2025, Zverev won his opening round-robin matches against Thiago Monteiro and Zhang Zhizhen but withdrew from his next match due to a bicep strain injury. Team Germany then failed to progress to the quarterfinals, failing to defend their title. In 2026, Zverev defeated Tallon Griekspoor in straight sets and won the mixed doubles match alongside Laura Siegemund to secure the tie over Netherlands. In their next tie against Poland, Zverev lost in straight sets to Hubert Hurkacz, who was making a return from a seven-month hiatus due to injury.
Although the Cossacks were sometimes portrayed by Bolsheviks, and later by émigré historians, as a monolithic counterrevolutionary group during the civil war, there were many Cossacks who fought with the Red Army throughout the conflict, known as Red Cossacks. Many poorer Cossack communities also remained receptive to the communist message. In late 1918 and early 1919, widespread desertion and defection among Don, Ural, and Orenburg Cossacks fighting with the Whites produced a military crisis that was exploited by the Red Army in those sectors. After the main White armies were defeated in early 1920, many Cossack soldiers switched their allegiance to the Bolsheviks, and fought with the Red Army against the Poles and in other operations. On 22 December 1917, the Council of People's Commissars effectively abolished the Cossack estate by ending their military service requirements and privileges. After the widespread anticommunist rebellions among Cossacks in 1918, the Soviet regime's approach hardened in early 1919, when the Red Army occupied Cossack districts in the Urals and northern Don. The Bolsheviks embarked on a policy of "de-Cossackization", intended to end the Cossack threat to the Soviet regime. This was pursued through resettlement, widespread executions of Cossack veterans from the White armies, and favoring the outlanders within the Cossack hosts. Ultimately, the de-Cossackization campaign led to a renewed rebellion among Cossacks in Soviet-occupied districts and produced a new round of setbacks for the Red Army in 1919.
=== Repair of Oxidative damage === Secondary defenses include DNA-repair systems, proteolytic and lipolytic enzymes. DNA repair enzymes include endonuclease IV, induced by oxidative stress, and exonuclease III, induced in the stationary phase and in starving cells. These enzymes act on duplex DNA and clean up DNA 3' terminal ends. Prokaryotic cells contain catalysts that modify the primary structure of proteins frequently by reducing disulfide bonds. This occurs in the following steps: (i) thioredoxin reductase transfers electrons from NADPH to thioredoxin via a flavin carrier (ii) glutaredoxin is also able to reduce disulfide bonds, but using GSH as an electron donor (iii) protein disulfide isomerase facilitates disulfide exchange reactions with large inactive protein substrates, besides having chaperone activity Oxidation of surface exposed methionine residues surrounding the entrance to the active site could function as a “last-chance” antioxidant defense system for proteins.
Sources: en.wikipedia.org
Polydimethylsiloxane (PDMS) Poly(caprolactone (PCL) Poly(lactide) (PLA) Poly(methyl methacrylate) (PMMA) If enough of the block copolymer molecules that make up a polymersome are cross-linked, the polymersome can be made into a transportable powder. Polymersomes can be used to make an artificial cell if hemoglobin and other components are added. The first artificial cell was made by Thomas Chang.
==== Absorption ==== The absolute bioavailability of suvorexant is 82% at a dose of 10 mg. Suvorexant exposure does not increase dose-proportionally over a dose range of 10 to 100 mg, which is likely due to decreased absorption at higher doses. Exposure to suvorexant increases by about 75% with a doubling of dose from 20 mg to 40 mg. The time to peak levels of suvorexant is 2 to 3 hours regardless of dose but with wide variation (range 30 minutes to 8 hours). Taking suvorexant with food does not modify suvorexant peak levels or area-under-the-curve levels (overall exposure) but does delay the time to peak concentrations by about 1.5 hours. Steady-state levels of suvorexant with once-daily continuous administration are reached within 3 days. Levels of suvorexant accumulate minimally, by about 1.2- to 1.6-fold, with repeated once-daily administration.
where χi denotes the mole fraction of component i. For greater accuracy, the critical point can be calculated using equations of state, such as the Peng–Robinson, or group-contribution methods. Other properties, such as density, can also be calculated using equations of state.
Sources: en.wikipedia.org
It is a synthetic peptide. Its design was inspired by a fragment of a protein found in human gastric juice, but the fifteen-amino-acid molecule itself is made in a laboratory and is not a normal component of food or of human tissue in appreciable amounts.
The number is an internal laboratory designation from the research group that first described the fragment. It does not encode a molecular weight, a receptor target, or a measured biological effect, and it carries no meaning outside the naming history of the compound.
It contains fifteen amino acid residues and has a calculated mass of roughly 1419.5 daltons. That places it in the short-peptide range, well below the size of small proteins, which affects how it is synthesized, purified, and analyzed.
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.